Infliximab induces a dysregulated tissue-homing profile on human T-lymphocytes in-vitro: a novel mechanism for paradoxical inflammation?
Simon T
ST
Peake
David
D
Bernardo
Elizabeth R
ER
Mann
Hafid O
HO
Al-Hassi
Stella C
SC
Knight
Ailsa L
AL
Hart
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D060887:B7 Antigens / Q000378:metabolism; D002478:Cells, Cultured; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D000069285:Infliximab; D054398:Receptors, CCR4 / Q000378:metabolism; D054400:Receptors, CCR7 / Q000378:metabolism; D016201:Receptors, Lymphocyte Homing / Q000378:metabolism*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D060887:B7 Antigens; C515354:CCR4 protein, human; C515370:CCR7 protein, human; D005765:Gastrointestinal Agents; D054398:Receptors, CCR4; D054400:Receptors, CCR7; D016201:Receptors, Lymphocyte Homing; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab